ライフサイエンスコーパス: prophylactic mastectomy

1 Contralateral prophylactic mastectomy.

2 d incidental breast cancer detected during a prophylactic mastectomy.

3 t cancer; 4,969 patients chose contralateral prophylactic mastectomy.

4 terval cancers, and 25 cancers discovered at prophylactic mastectomy.

5 No cancers occurred in women who underwent prophylactic mastectomy.

6 rs expected in our cohort had they not had a prophylactic mastectomy.

7 mong their 403 sisters who had not undergone prophylactic mastectomy.

8 pected in these two groups in the absence of prophylactic mastectomy.

9 r include surveillance, chemoprevention, and prophylactic mastectomy.

10 to surgery, mastectomies, and contralateral prophylactic mastectomies.

11 Fifty-six patients (5%) underwent bilateral prophylactic mastectomy; 1,004 chose surveillance with (

12 nt at one year, 34 percent at five years) or prophylactic mastectomy (17.3 percent at one year, 30.4

13 of breast cancer who had undergone bilateral prophylactic mastectomy: 214 at high risk and 425 at mod

14 re diagnosed before the respective proband's prophylactic mastectomy, 38 were diagnosed afterward, an

15 Among 519 women who underwent contralateral prophylactic mastectomy, 86.5% were satisfied with their

16 as 75.9% including the cancers discovered at prophylactic mastectomy (95% confidence interval: 69.5%,

17 e mailed surveys to women with contralateral prophylactic mastectomy after breast cancer diagnosis be

18 rom 2.9 to 5.3 years of life expectancy from prophylactic mastectomy and from 0.3 to 1.7 years of lif

19 in two (1.9%) of 105 women who had bilateral prophylactic mastectomy and in 184 (48.7%) of 378 matche

20 Prophylactic mastectomy and oophorectomy are often consi

21 s for women with cancer, and the efficacy of prophylactic mastectomy and oophorectomy in preventing b

22 years for mutation carriers undergoing both prophylactic mastectomy and oophorectomy.

23 In a decision analysis, we compared prophylactic mastectomy and prophylactic oophorectomy wi

24 Prophylactic mastectomy and prophylactic oophorectomy, e

25 re mutation carriers who underwent bilateral prophylactic mastectomy and who were followed prospectiv

26 nd prophylactic oophorectomy, 3.5 years with prophylactic mastectomy, and 4.9 years with both surgeri

27 he data on the outcomes for surveillance and prophylactic mastectomy are incomplete.

28 We determined the rate of contralateral prophylactic mastectomy as a proportion of all surgicall

29 east cancer and elected to undergo bilateral prophylactic mastectomy at a large, tertiary US health c

30 irteen patients (9.6%) underwent a bilateral prophylactic mastectomy at a median of 23 months followi

31 ory of breast cancer who underwent bilateral prophylactic mastectomy at the Mayo Clinic between 1960

32 moprevention, and those undergoing bilateral prophylactic mastectomies between 1980 and 2009.

33 reast cancer on the basis of family history, prophylactic mastectomy can significantly reduce the inc

34 y high among patients choosing contralateral prophylactic mastectomy, complications and procedure ext

35 The growing rate of contralateral prophylactic mastectomy (CPM) among women diagnosed as h

36 ision-making process regarding contralateral prophylactic mastectomy (CPM) among women with sporadic

37 ienced by patients who undergo contralateral prophylactic mastectomy (CPM) and breast reconstruction.

38 ne national temporal trends in contralateral prophylactic mastectomy (CPM) and determine whether surv

39 in BRCA1/2 genes) who opt for contralateral prophylactic mastectomy (CPM) have a substantially reduc

40 anslation BACKGROUND: Rates of contralateral prophylactic mastectomy (CPM) have increased dramaticall

41 e investigated the efficacy of contralateral prophylactic mastectomy (CPM) in reducing contralateral

42 Contralateral prophylactic mastectomy (CPM) is one option for reducing

43 Contralateral prophylactic mastectomy (CPM) rates in women with unilat

44 Guidelines assert that contralateral prophylactic mastectomy (CPM) should be discouraged in p

45 rcinoma in situ (DCIS) undergo contralateral prophylactic mastectomy (CPM) to prevent cancer in the o

46 Contralateral prophylactic mastectomy (CPM) use is increasing among wo

47 The use of contralateral prophylactic mastectomies (CPMs) among patients with inv

48 The rate of contralateral prophylactic mastectomies (CPMs) continues to rise, alth

49 rvention increased the cost-effectiveness of prophylactic mastectomy for BRCA1 mutation carriers to 7

50 Data on the efficacy of bilateral prophylactic mastectomy for breast cancer risk reduction

51 The use of contralateral prophylactic mastectomy in the United States more than d

52 etermine the use and trends of contralateral prophylactic mastectomy in the United States.

53 be reduced significantly after contralateral prophylactic mastectomy in women with a personal and fam

54 dy suggests that positive outcomes following prophylactic mastectomy include decreased emotional conc

55 Prophylactic mastectomy is a preventive option for women

56 tation carriers with no history of bilateral prophylactic mastectomy matched to cases on gene, center

57 patients with negative MR findings underwent prophylactic mastectomy; no malignancy was found.

58 f life was not associated with contralateral prophylactic mastectomy or demographic characteristics,

59 P < .001), and the increase was greatest for prophylactic mastectomy or therapeutic mastectomy for in

60 (OR, 1.73; 95% CI, 1.62-1.85), contralateral prophylactic mastectomy (OR, 1.48; 95% CI, 1.23-1.77), a

61 edical oncologists and surgeons to recommend prophylactic mastectomy (P < .001), as were physicians i

62 e imaging (MRI) from ages 25 to 69 years and prophylactic mastectomy (PM) and/or prophylactic oophore

63 ance imaging (MRI) from ages 25 to 69 years, prophylactic mastectomy (PM) at various ages, and/or pro

64 rophylactic surgery, our model suggests that prophylactic mastectomy provides substantial gains in li

65 Likewise, the contralateral prophylactic mastectomy rate for patients undergoing mas

66 d during the study period, the contralateral prophylactic mastectomy rate increased.

67 Bilateral prophylactic mastectomy reduced the risk of breast cance

68 Bilateral prophylactic mastectomy reduces the risk of breast cance

69 Most women undergoing contralateral prophylactic mastectomy report satisfaction with their d

70 Prophylactic mastectomy should be considered on an indiv

71 None of the 84 prophylactic mastectomies showed nipple involvement by I

72 e incidental breast cancer was detected in a prophylactic mastectomy specimen.

73 when including and not including cancers in prophylactic mastectomy specimens, respectively).

74 investigated on breast tissues excised from prophylactic mastectomy specimens.

75 41 women with no history of breast cancer or prophylactic mastectomy, the incidence of breast cancer

76 Beyond prophylactic mastectomy, there are currently very few op

77 1.4% of physicians would recommend bilateral prophylactic mastectomy to a 38-year-old BRCA1 mutation

78 Mean time from prophylactic mastectomy to last follow-up was 14.5 years

79 BRCA1-mutation carriers) frequently undergo prophylactic mastectomy to minimize their risk of breast

80 nilateral breast cancer choose contralateral prophylactic mastectomy to prevent cancer in the opposit

81 Contralateral prophylactic mastectomy use is substantial among patient

82 ions for preference-based procedures such as prophylactic mastectomy vary by physician characteristic

83 ncer is reviewed to help guide the choice of prophylactic mastectomies vs breast-conserving therapy.

84 The median age at prophylactic mastectomy was 42 years.

85 Thus, prophylactic mastectomy was associated with a reduction

86 Prophylactic mastectomy was observed to significantly re

87 have a mutation, would be likely to undergo prophylactic mastectomy, whereas 12% of nurse practition

88 arian cancer risk by 45%, and that bilateral prophylactic mastectomy would reduce breast cancer risk